Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTYX vs PHAR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PHAR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

PHAR Overall Winner 6-Pillar Tally: VTYX 1 – 5 PHAR Matrix Metrics: VTYX 4 – 5 PHAR

As of Nov 16, 2026, Pharming Group N.V. ADS, each representing 10 (PHAR) is the stronger overall head-to-head candidate over Ventyx Biosciences, Inc. (VTYX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTYX carries a Unified Composite Score of 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin), whereas PHAR carries 36.2/100 (SELL) at $12.58 (N/M Forward P/E, 12.8% operating margin).

  • Composite vs. Pillar Nuance: While VTYX currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. PHAR 36.2/100 SELL), PHAR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.8% vs. 0.0% operating margin) and revenue trajectory (+20.8% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTYX vs PHAR
VTYX NASDAQ
Ventyx Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$14.00
+0.14% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.07β · 2% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (19.0% over 20 days), RSI 71
RSI-14: 70.7 · SMA20: $13.96 · SMA50: $12.72
PHAR NASDAQ Head-to-Head Winner
Pharming Group N.V. ADS, each representing 10 ordinary shares
Pharmaceutical Preparations
$12.58
-0.16% 1D
Market Cap $891.8M
TTM Revenue $387M
Forward P/E N/M
Beta / 30D Vol 0.83β · 60% Vol
Unified Composite Score
36.2 / 100 SELL
Tech 27.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.6% over 20 days), RSI 58
RSI-14: 58.1 · SMA20: $12.11 · SMA50: $10.98

6-Pillar Scorecard Institutional Category Breakdown (VTYX 1 – 5 PHAR)

Columns: Metric · VTYX · PHAR
1. Valuation Multiples PHAR
Forward P/E N/M N/M
Trailing P/E N/M 39.4x
PEG Ratio N/M N/M
EV / Revenue N/M 2.3x
2. Growth & Scale PHAR
Revenue Growth (YoY) +0.0% +20.8%
Earnings Growth (YoY) +0.0% +74.9%
TTM Revenue (USD) N/A $387M
Market Cap $1.0B $891.8M
3. Profitability & Quality PHAR
Gross Margin N/A 87.7%
Operating Margin 0.0% 12.8%
Net Profit Margin 0.0% 6.2%
Return on Equity (ROE) -45.4% 8.7%
4. Balance Sheet & Cash Flow PHAR
Cash Generation (TTM) N/A $57M EBITDA
Cash Flow Margin N/A 14.7% EBITDA Mgn
Net Cash / Leverage $2.68 Book/Sh · -45.4% ROE $4.26 Book/Sh · 8.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTYX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 0.5% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat PHAR
OpEx & R&D Intensity N/A 74.9% of Rev ($290M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTYX (4) vs PHAR (5)
Institutional Metric VTYX PHAR Criterion Row Edge
Market Capitalization
Scale
$1.0B $891.8M Larger Scale VTYX
Trailing P/E Ratio
Valuation
N/M 39.4x Lower Multiple PHAR
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +20.8% Higher Growth PHAR
Operating Margin (TTM)
Profitability
0.0% 12.8% Higher Margin PHAR
Net Profit Margin
Profitability
0.0% 6.2% Higher Margin PHAR
Return on Equity (ROE)
Capital Efficiency
-45.4% 8.7% Higher ROE PHAR
52-Week Range Position
Momentum
55% ($1–$25) 28% ($9–$21) Stronger Trend VTYX
Beta / 30D Volatility
Risk Regime
2.07β · 2% Vol 0.83β · 60% Vol Lower Realized Risk VTYX
Unified Institutional Score
Composite Signal
50.4 / 100 (HOLD) 36.2 / 100 (SELL) Higher Composite VTYX
Trailing 12M Revenue (USD)
Operating Scale
N/A $387M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 87.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($2.68 Book/Sh · -45.4% ROE) $57M EBITDA ($4.26 Book/Sh · 8.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTYX +25.13 pp
VTYX: +0.36% · PHAR: -24.77%
3M Horizon VTYX +52.0 pp
VTYX: +40.0% · PHAR: -12.0%
6M Horizon VTYX +59.2 pp
VTYX: +46.6% · PHAR: -12.6%
1Y Horizon VTYX +59.2 pp
VTYX: +46.6% · PHAR: -12.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VTYX vs PHAR. Trailing 12-month operating profitability (VTYX 0.0% vs PHAR 12.8%) and valuation multiples (VTYX N/M vs PHAR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VTYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-45.4% · N/M
PHAR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$387M
Gross Margin87.7%
Op. Margin12.8%
ROE / Fwd P/E8.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PHAR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PHAR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTYX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PHAR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $891.8M market capitalization and 12.8% operating margin.
OpEx & R&D Reinvestment 74.9% of Rev ($290M)
90D Engineering Disclosures 0 Published

Investor FAQ VTYX vs PHAR Key Questions & Quantitative Answers

As of Nov 16, 2026, Pharming Group N.V. ADS, each representing 10 (PHAR) is the stronger overall head-to-head candidate over Ventyx Biosciences, Inc. (VTYX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VTYX carries a Unified Composite Score of 50.4/100 (HOLD) at $14.00 (N/M Forward P/E, 0.0% operating margin), whereas PHAR carries 36.2/100 (SELL) at $12.58 (N/M Forward P/E, 12.8% operating margin). Composite vs. Pillar Nuance: While VTYX currently prints a higher short-term Unified Composite Score (50.4/100 HOLD vs. PHAR 36.2/100 SELL), PHAR captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (12.8% vs. 0.0% operating margin) and revenue trajectory (+20.8% vs. +0.0% YoY).

PHAR leads the Growth & Scale pillar: VTYX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PHAR at +20.8% YoY revenue growth and +74.9% YoY earnings growth on $387M TTM revenue (87.7% gross margin, 12.8% operating margin). On trailing 12-month operating scale, VTYX generates N/A in USD-normalized revenue versus $387M for PHAR. In operating R&D and SG&A reinvestment, VTYX deploys N/A (0 90-day corporate R&D disclosures) versus 74.9% of Rev ($290M) (0 disclosures) for PHAR.

PHAR screens cheaper on headline valuation multiples. VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PHAR trades at N/M Forward P/E, 39.4x Trailing P/E, N/M PEG, and 2.3x EV/Revenue (14.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTYX (-45.4% ROE) versus PHAR (8.7% ROE) capital efficiency.

In options market volatility and institutional positioning, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk). By comparison, PHAR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.83β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.